A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and ...
The middle meningeal artery (MMA) has emerged as a potential therapeutic target for severe, treatment-resistant headache syndromes. Growing evidence suggests that the MMA and its dural branches are ...
Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results